Kennedy Capital Management, Inc. Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Kennedy Capital Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$27.51 - $57.29 $1.78 Million - $3.71 Million	-64,799 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$40.86 - $57.65 $53,363 - $75,290	-1,306 Reduced 1.98%	64,799 $3.53 Million
Q3 2019 Nov 14, 2019	BUY	$37.38 - $49.47 $1.78 Million - $2.36 Million	47,725 Added 259.66%	66,105 $2.76 Million
Q2 2019 Aug 14, 2019	BUY	$39.79 - $67.01 $43,928 - $73,979	1,104 Added 6.39%	18,380 $805,000
Q1 2019 May 13, 2019	SELL	$34.52 - $53.29 $590,050 - $910,885	-17,093 Reduced 49.73%	17,276 $889,000
Q4 2018 Feb 12, 2019	SELL	$29.75 - $42.9 $1.32 Million - $1.91 Million	-44,476 Reduced 56.41%	34,369 $1.27 Million
Q3 2018 Nov 14, 2018	BUY	$32.79 - $43.0 $2.59 Million - $3.39 Million	78,845 New	78,845 $2.96 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.